Why Vera Therapeutics Stock Crushed it Today
If all goes well, the company will have a drug on the market that could bring in billions of dollars […]
Therapeutics
MiNK Therapeutics (INKT) Earnings Call Transcript
Image source: The Motley Fool. DATE Friday, November 14, 2025 at 8:30 a.m. ET CALL PARTICIPANTS Chief Executive Officer —
Is Tango Therapeutics Stock a Buy, Sell, or Hold After Major Shareholder Third Rock Ventures Sold Nearly Half a Million Shares?
Venture capital fund Third Rock Ventures IV, L.P., a 10% owner of Tango Therapeutics, Inc. (TNGX +1.79%), reported the sale
Biotech Stocks Positioned to Transform Treatment With Next-Gen Therapeutics
Naples, FL, September 26th, 2025, FinanceWire Naples, FL, September 26th, 2025, NewsDirect Biotech is entering a new era of drug
NRx Pharmaceuticals (NASDAQ: NRXP) Subsidiary HOPE Therapeutics Closes Acquisition of Dura Medical
Austin, Texas, United States, September 9th, 2025, FinanceWire NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced that its wholly
Why Viking Therapeutics Stock Popped Nearly 4% Today
Numerous companies in the healthcare sector are feverishly busy developing obesity drugs, as these products have taken the medical world
PTC Therapeutics CRL ‘expected,’ focus moves to Sephience, says RBC Capital
PTC Therapeutics (PTCT) on Tuesday announced that they received a complete response letter for vatiquinone in Friedreich’s ataxia, with the
Is Viking Therapeutics the Next Big Biotech Bet?
Explore the exciting world of Viking Therapeutics (NASDAQ: VKTX) with our contributing expert analysts in this Motley Fool Scoreboard episode.
Could Viking Therapeutics Become the Next Eli Lilly?
The obesity treatment market is booming, with groundbreaking drugs like Eli Lilly‘s (LLY 2.28%) Zepbound delivering transformative patient results and
Featured
Atossa Therapeutics CEO Steven Quay buys $9,886 in common stock
Atossa Therapeutics CEO Steven Quay buys $9,886 in common stock Source link